Immunotherapy Drug Can Lower Recurrence When Bladder Cancer Spreads
Matthew Galsky, MD, discusses his long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer. He said, “These results support adjuvant nivolumab as a standard of care for high-risk [patient with] muscle-invasive urothelial carcinoma after radical surgery.
Researchers Discover Why One Type of Chemotherapy Works Best in Bladder Cancer
Jan 26, 2024 View All Press Releases
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press ReleasesCombination of Chemo and Immunotherapy Is Shown to Work Against Metastatic Bladder Cancer
May 15, 2020 View All Press Releases